Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.32 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.31 |
| ▸ | FEN1 | P39748 | 3/20 | 0.30 |
| ▸ | NOS3 | P29474 | 2/20 | 0.30 |
| ▸ | NOS2 | P35228 | 2/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10221991 | 0.80 | MEN1 (0.32) | MEN1KMT2ATTBK1ALOX5APFEN1 | |
| SCHEMBL11523536 | 0.79 | MEN1 (0.38) | NUDT1MEN1KMT2AALOX5APKDM4E | |
| SCHEMBL9593913 | 0.77 | NOS2 (0.44) | MEN1KMT2AALOX5APKDM4EHSD17B10 | |
| SCHEMBL6468946 | 0.77 | MEN1 (0.41) | NUDT1MEN1KMT2AKDM4EHSD17B10 | |
| SCHEMBL21325538 | 0.76 | NUDT1 (0.36) | NUDT1 | |
| SCHEMBL13447545 | 0.73 | NOS2 (0.47) | MEN1KMT2AKDM4EHSD17B10NOS3 | |
| SCHEMBL16679336 | 0.72 | MEN1 (0.39) | MEN1KMT2AALOX5APFEN1 | |
| SCHEMBL6708077 | 0.72 | KCNH2 (0.42) | MEN1KMT2AKDM4EHSD17B10NOS2 | |
| SCHEMBL16679299 | 0.72 | MEN1 (0.36) | MEN1KMT2AALOX5APFEN1NOS3 | |
| SCHEMBL1725245 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100069347-A1 | HETEROCYCLYL-SUBSTITUTED ANTI-HYPERCHOLESTEROLEMIC COMPOUNDS | MERCK SHARP & DOHME CORP. | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069347-A1 | HETEROCYCLYL-SUBSTITUTED ANTI-HYPERCHOLESTEROLEMIC COMPOUNDS | LDLR, PCSK9, CYP46A1 | NUDT1 574/4885MEN1 1189/4885KMT2A 1716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.